Dennis W. Raisch
University of New Mexico
167 Papers
993 Citations
Dennis W. Raisch is an academic researcher from University of New Mexico. The author has contributed to research in topics: Medicine & Adverse Event Reporting System. The author has an hindex of 42, co-authored 165 publications. Previous affiliations of Dennis W. Raisch include University of South Carolina & University of Texas Health Science Center at San Antonio.
Chat about Author
Papers
Direct health care costs of 4 common skin ulcers in New Mexico Medicaid fee-for-service patients.
Ritesh N Kumar,Gireesh V. Gupchup,Melanie A. Dodd,Bijal M. Shah,Michael Iskedjian,Thomas R. Einarson,Dennis W. Raisch +6 more
TL;DR: The New Mexico Medicaid fee-for-service system incurred a total cost of approximately $11.6 million from 1994 through 1998 for the treatment of the 4 categories of skin ulcers studied, which showed that the majority of wounds were coded as pressure ulcers, which had the highest associated costs.
40
Polysorbate 80 hypersensitivity reactions: a renewed call to action
LeAnn B. Norris,Zaina P. Qureshi,P. Brandon Bookstaver,Dennis W. Raisch,Oliver Sartor,Hao Chen,Fei Chen,Charles L. Bennett +7 more
TL;DR: This study aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the concrete mechanical properties of EMTs and their effects on a patients' health.
38
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).
Charles L. Bennett,Charles L. Bennett,Charles L. Bennett,David Spiegel,Iain C. Macdougall,LeAnn B. Norris,LeAnn B. Norris,Zaina P. Qureshi,Zaina P. Qureshi,Oliver Sartor,Stephen Y. Lai,Martin S. Tallman,Dennis W. Raisch,Sheila Weiss Smith,Samuel M. Silver,Alanna Murday,Alanna Murday,James Olen Armitage,David Goldsmith +18 more
TL;DR: ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels.
37
Quitting Patterns and Predictors of Success Among Participants in a Tobacco Cessation Program Provided by Pharmacists in New Mexico
TL;DR: Having community pharmacists provide smoking cessation interventions resulted in quitting success rates similar to other health care professionals, which ranged from 9.9% to 26.0%.
36
Health-related quality of life changes associated with buprenorphine treatment for opioid dependence
Dennis W. Raisch,Dennis W. Raisch,Heather M Campbell,David A. Garnand,Mark A. Jones,Mike R. Sather,Mike R. Sather,Rupali K. Naik,Walter Ling +8 more
TL;DR: Buprenorphine, accompanied with psychosocial counseling, was associated with improved HRQOL and HUs and there were no significant differences in opioid-positive urines, dropout rates, or dosage changes between formulations.
36